PUBLICATIONS
Phase 2A biomarker analyses linked APG-157 treatment to reduced HPV16 and NF-κB signaling, increased gigaxonin and activation of systemic immune pathways.
Presented by Jonathan D. Schoenfeld, MD. Trial-in-progress presentation of AVTA-30-01, a global randomized Phase 3 study across surgical and nonsurgical pathways.
Spatial profiling showed APG-157 remodeling immune-cold tumors into immune-engaged states with coordinated cytotoxic and helper T-cell organization.
Phase 2A results reported disease control, deep ctDNA reductions, clinical-to-pathological downstaging and a favorable safety profile.
PEER-REVIEWED PUBLICATIONS
APG-157 reprogrammed innate immune cells and produced durable remission in an immune-intact glioblastoma model.
APG-157 enhanced checkpoint blockade and improved tumor control by reshaping the tumor immune environment.
Cell-free RNA revealed early immune and inflammatory responses to APG-157 through a non-invasive blood test.
Oral APG-157 demonstrated systemic absorption, reduced inflammatory signals and increased T-cell recruitment into the tumor.
For scientific inquiries, collaboration opportunities or access to supporting materials, contact our team.